Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL

Gene Section Short Communication

SOCS6 (suppressor of cytokine signaling 6)

Julhash U Kazi, Amilcar Flores-Morales, Lars Rönnstrand

Division of Translational Cancer Research and Lund Stem Cell Center, Lund University, Lund, Sweden (JUK, LR), Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark (AFM)

Published in Atlas Database: May 2014

Online updated version : http://AtlasGeneticsOncology.org/Genes/SOCS6ID42351ch18q22.html DOI: 10.4267/2042/55379

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

The suppressor of cytokine signaling (SOCS) family of proteins are well known negative regulators of cytokine receptors signaling consisting of eight structurally similar proteins, SOCS1-7 and CIS. A key feature of this family of proteins is the presence of two structural motifs: a centrally located SH2 domain and a SOCS box in the C-terminus. The SOCS box mediates the interaction with the Elongins B and C complex while an additional motif mediates its interaction with Cullin 5 to assemble a Cullin/Ring ubiquitin ligase. In this complex SOCS6 acts as a substrate recognition subunit through interactions mediated by the N-terminus and the SH2 domain. SOCS6 interacts with tyrosine kinase receptors FLT3 and c-KIT and modulate their ubiquitination and function.

Keywords

CIS4; SSI4; CIS-4; SOCS4; STAI4; SOCS-4; SOCS-6; STATI4; HSPC060.

Identity

Other names: CIS-4, CIS4, HSPC060, SOCS-4, SOCS-6, SOCS4, SSI4, STAI4, STATI4

HGNC (Hugo): SOCS6

Location: 18q22.2

DNA/RNA

Description

According to Entrez-Gene SOCS6 maps to NC_000018.10 in the region between 70288901 and 70330199 on the plus strand. According to UCSC genome browser SOCS6 has two exons, one shorter of 190 base pairs and other on of 5656 base pairs.

Transcription

SOCS6 mRNA 5864 has nucleotides (NM_004232.3). The open reading frame (ORF) includes 1608 nucleotides situated in exon 2 (Figure 1). Transcription is induced by activation of certain cytokine receptors and growth factor receptors.

Pseudogene

Chromosome 11q14.1 has a SOCS6 pseudogene in between 83789973 and 83791578 spanning 1606 base pairs. The pseudogene has a 92% sequence similarity with the SOCS6 gene.



Figure 1: SOCS6 mapped on Human Dec. 2013 (GRCh38/hg38) assembly in chromosome 18: (70288901-70330198) spanning 41298 base pairs using UCSC Genome Browser.





SH2 SB

Figure 2: Domain structure of SOCS6 protein, SB stand for SOCS-box.

Protein

Description

SOCS6 gene is expressed as an approximately 60 kDa protein with calculated isoelectric point 6.83 and total charge -0.76 at pH 7.

SOCS6 has a still uncharacterized long N-terminal region, an SH2 domain and a C-terminal SOCS-box (Figure 2).

The protein is mainly expressed in the cytosol and associates with multiple proteins (Bayle et al., 2004; Bayle et al., 2006; Hwang et al., 2007; Kazi et al., 2012; Zadjali et al., 2011).

Most relevant for SOCS6 function is its capacity to associate with Elongin B and Elongin C and with Cullin 5 to assemble a functional E3 ubiquitin ligase complex.

Expression

SOCS6 is highly to moderately expressed in heart, parathyroid, salivary gland, stomach, thyroid, kidney and skeletal muscle tissues. Expression was also reported in mature hematopoietic cells and melanocyte.

Localisation

SOCS6 predominantly localizes to the cytosol and nucleus (Hwang et al., 2007). The N-terminal amino acids 1-210 influence its nuclear localization. Additionally SOCS6 localizes to the mitochondria and probably to the inner-surface of cell membrane (Lin et al., 2013).

Function

SOCS6 is involved in protein destabilization and to some extent acts as a signaling molecule. The presence of multiple domains in SOCS6 protein facilitates interaction with multiple signaling molecules. The SOCS6 SH2 domain associates with specific tyrosine phosphorylated proteins and the SOCS-box recruits the ubiquitin machinery directing proteins for degradation (Kazi et al., 2014; Zadjali et al., 2011).

Homology

Homologous proteins are found in various species including monkey, mouse, rat, frog and zebra fish etc. Monkey SOCS6 displays as high as 98% sequence similarity to human SOCS6, while zebra fish SOCS6 display 68% sequence similarity. In any case, the SOCS-box sequence is highly conserved and maintains a 100% sequence similarity.

Mutations

Note

In the COSMIC database 52 different SOCS6 mutations have been listed, where 40 mutations are non-synonymous (figure 3), two mutations introduce stop codons at 199 and 328 sites, one mutation is reported as a 254A and 255G deletion and the other 9 mutations are synonymous mutations.

Implicated in

Hepatocellular carcinoma

Note

SOCS6 expression is significantly reduced in hepatocellular carcinoma and lower SOCS6 correlates with overall and disease free survival (Qiu et al., 2013).

Lung squamous cell carcinoma

Note

Loss of SOCS6 function is associated with poor prognosis in primary lung squamous cell carcinoma. Copy number loss and slight hypermethylation that was correlated with disease progression was reported in this disease (Sriram et al., 2012).

Figure 3: Mutations in SOCS6 protein according to COSMIC database.

Prostate cancer

Note

The down-regulation of SOCS6 has been reported in prostate cancer tissues with a higher Gleason score, the advanced pathological stage, positive metastasis, and the positive PSA failure suggesting that SOCS6 might be associated with aggressive progression of prostate cancer (Zhu et al., 2013).

Gastric cancer

Note

Loss of SOCS6 function has been reported in gastric cancer. Allelic loss and promoter hypermethylation occur in this cancer. Ectopic expression of SOCS6 led to reduced cell growth and colony formation of gastric cancer cell (Lai et al., 2010).

Pancreatic cancer

Note

The microRNA miR-424-5p is a suppressor of SOCS6 expression. This microRNA is up-regulated in pancreatic cancer resulting in down-regulation of SOCS6 (Wu et al., 2013). Down-regulation of SOCS6 led to increased proliferation, migration and invasion of pancreatic cancer cells suggesting SOCS6 acts as a tumor suppressor in pancreatic cancer.

Glucose metabolism

Note

SOCS6 has been shown to interact with the insulin receptor (INSR), INSR substrates IRS2 and IRS4, and negatively regulates insulin signaling (Krebs et al., 2002; Mooney et al., 2001). Although these findings suggest that SOCS6 might play a role in glucose metabolism, mice lacking SOCS6 gene did not display any significant defects in glucose metabolism apart from a slight growth retardation (Krebs et al., 2002).

References

Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem. 2001 Jul 13;276(28):25889-93

Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, De Souza DP, Hanzinikolas K, Eyles J, Connolly LM, Simpson RJ, Nicola NA, Nicholson SE, Baca M, Hilton DJ, Alexander WS. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002 Jul;22(13):4567-78

Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P.

Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem. 2004 Mar 26;279(13):12249-59

Bayle J, Lopez S, Iwaï K, Dubreuil P, De Sepulveda P. The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett. 2006 May 15;580(11):2609-14

Hwang MN, Min CH, Kim HS, Lee H, Yoon KA, Park SY, Lee ES, Yoon S. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun. 2007 Aug 24;360(2):333-8

Lai RH, Hsiao YW, Wang MJ, Lin HY, Wu CW, Chi CW, Li AF, Jou YS, Chen JY. SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett. 2010 Feb 1;288(1):75-85

Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, Rönnstrand L, Knapp S, Bullock AN, Flores-Morales A. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem. 2011 Jan 7;286(1):480-90

Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem. 2012 Oct 19;287(43):36509-17

Sriram KB, Larsen JE, Savarimuthu Francis SM, Wright CM, Clarke BE, Duhig EE, Brown KM, Hayward NK, Yang IA, Bowman RV, Fong KM. Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One. 2012;7(2):e30398

Lin HY, Lai RH, Lin ST, Lin RC, Wang MJ, Lin CC, Lee HC, Wang FF, Chen JY. Suppressor of cytokine signaling 6 (SOCS6) promotes mitochondrial fission via regulating DRP1 translocation. Cell Death Differ. 2013 Jan;20(1):139-53

Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y. Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem. 2013 Jun;378(1-2):99-106

Wu K, Hu G, He X, Zhou P, Li J, He B, Sun W. MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res. 2013 Oct;19(4):739-48

Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN, Chen WH, Sun ZL, Zhong WD. Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem. 2013 Sep;381(1-2):51-9

Kazi JU, Kabir NN, Flores-Morales A, Rönnstrand L. SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci. 2014 Sep;71(17):3297-310

This article should be referenced as such:

Kazi JU, Flores-Morales A, Rönnstrand L. SOCS6 (suppressor of cytokine signaling 6). Atlas Genet Cytogenet Oncol Haematol. 2015; 19(1):50-52.